|
|
Clinical effect of Entecavir combined with Adefovir Dipivoxil in the treatment of chronic hepatitis B |
WANGYan-yan |
Department of Infectious Diseases,Nanchang Third Hospital,Jiangxi Province,Nanchang 330009,China |
|
|
Abstract Objective To explore the clinical effect of Entecavir and Adefovir Dipivoxil in the treatment of chronic hepatitis B.Methods A total of 60 patients with chronic hepatitis B who were admitted to our hospital from February 2018 to February 2019 were selected as the research objects.and they were divided into observation group (odd number patients)and control group (even number patients)using the single and double number method,30 cases in each group.Patients in the control group were treated with Adefovir Dipivoxil,and patients in the observation group were treated with Entecavir combined with Adefovir Dipivoxil.The levels of total bilirubin (TBil),alanine aminotransferase(ALT)and albumin(ALB),the total effective rate of clinical treatment,and the total incidence of adverse reactions were compared between the two groups of patients before and after treatment.Results There were no significant differences in TBil,ALT and ALB between the two groups before treatment(P>0.05).After treatment,the levels of TBil and ALT in the observation group were lower than those in the control group,while the level of ALB was higher than that in the control group,with statistically significant differences (P<0.05).The total effective rate of the test group was 93.00%,higher than that of the control group(70.00%),and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Entecavir combined with Adefovir Dipivoxil in the treatment of chronic hepatitis B can effectively improve the level of TBil,ALT and ALB,and increase the total effective rate of clinical treatment.and reduce the incidence of adverse reactions.It is worthy of clinical application
|
Received: 11 March 2020
|
|
|
|
[1] |
杨冬冬.阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察[J].基层医学论坛,2017,19(8):934-935.
|
[2] |
徐鹤翔,梁利民,郑吉顺,等.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗HBeAg阳性慢性乙型肝炎96周疗效分析[J].医学理论与实践,2017,30(11):1611-1613.
|
[3] |
季晓磊,马臻,李建明,等.恩替卡韦与阿德福韦酯单药治疗HBeAg阳性慢性乙型肝炎的效果及安全性比较[J].中国综合临床,2018,34(2):142-146.
|
[4] |
赖玺杰,连江山,陈涧阳,等.拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎和乙型肝炎肝硬化患者替换为恩替卡韦单药治疗的疗效和安全性观察[J].中华肝脏病杂志,2018,26(2):113-118.
|
[5] |
卫李,卫志干.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗阿德福韦酯耐药的乙型肝炎肝硬化患者对比研究[J].临床医药文献电子杂志,2017,6(16):3103-3104.
|
[6] |
俞婷婷,常啸,叶英,等.恩替卡韦与阿德福韦酯单药治疗HBeAg阳性慢性乙型肝炎的疗效及安全性[J].江苏医药,2018,44(5):12-14.
|
[7] |
魏玉,李华河,张献波.恩替卡韦与阿德福韦酯治疗慢性乙型肝炎患者近期疗效和不良反应比较研究[J].实用肝脏病杂志,2018,21(3):453-454.
|
[8] |
雷锦辉,罗君.恩替卡韦初始单药与拉米夫定和阿德福韦酯联用对HBeAg阳性慢性乙型肝炎患者抗病毒的疗效比较[J].抗感染药学,2017,50(4):126-128.
|
[9] |
连佳,韩涛,向慧玲,等.恩替卡韦与阿德福韦酯单药治疗慢性乙型肝炎相关性肝病患者240周的随机对照研究[J].中华肝脏病杂志,2015,23(10):733-737.
|
[10] |
陈雪.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗慢性乙型肝炎的效果和安全性比较研究[J].国际医药卫生导报,2016,27(21):3817.
|
[11] |
杨静.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗慢性乙肝的疗效比较[J].皖南医学院学报,2015,17(1):60-62.
|
[12] |
温晓娜,王楠,毛静怡,等.阿德福韦酯和恩替卡韦治疗慢性乙型肝炎患者疗效的Meta分析[C].中国药学会.第十三届青年药学科研成果交流会论文集,2016,9(27):550-557.
|
[13] |
闪海霞,李延玲.恩替卡韦结合CIK疗法治疗乙型肝炎病毒相关性肝癌的效果[J].广东医学,2015,36(23):3706-3708.
|
[14] |
王甜,秦波.恩替卡韦单药与拉米夫定及阿德福韦酯联合治疗慢性乙型肝炎初治患者疗效的Meta分析[J].中华实验和临床感染病杂志,2015,9(3):312-317.
|
[15] |
潘永.恩替卡韦联合阿德福韦酯对核苷类药物治疗失败慢性乙型肝炎患者临床疗效观察[J].淮海医药,2016,34(2):92-93,95.
|
|
|
|